These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25911688)

  • 1. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
    Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
    Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
    Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
    Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
    Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
    Rios-Doria J; Sabol D; Chesebrough J; Stewart D; Xu L; Tammali R; Cheng L; Du Q; Schifferli K; Rothstein R; Leow CC; Heidbrink-Thompson J; Jin X; Gao C; Friedman J; Wilkinson B; Damschroder M; Pierce AJ; Hollingsworth RE; Tice DA; Michelotti EF
    Mol Cancer Ther; 2015 Jul; 14(7):1637-49. PubMed ID: 25948294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
    Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
    Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway.
    Meira DD; Nóbrega I; de Almeida VH; Mororó JS; Cardoso AM; Silva RLA; Albano RM; Ferreira CG
    Eur J Cancer; 2009 May; 45(7):1265-1273. PubMed ID: 19167213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
    Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
    Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
    J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.